The headline reads as positive (95% confidence from the FinBERT financial-language model), so the stock went through the full analysis. The broader analysis agrees with the good news.
Stocks › RVMD
Revolution Medicines, Inc. (RVMD) stock analysis
BUY 39% confidence · analysed Oct 15, 2026
On Oct 15, 2026, our model rated Revolution Medicines, Inc. (RVMD) BUY with 39% confidence at a price of $190.97. That means most of the technical, fundamental, money-flow and news signals point to upside.
Analysed price$190.97
Trade plan from the model
The model's long / bullish plan uses an entry near $190.97, a target of $216.15 (+13.2%) and a stop-loss at $173.70 (-9.0%).
That is a reward-to-risk ratio of about 1.5 to 1: the potential gain is not much bigger than the loss, so the setup is marginal.
The plan has a time limit: reassess by Nov 3, 2026 whatever the price does.
Entry$190.97
Target$216.15
Stop-loss$173.70
Reassess byNov 3, 2026
The model's one-paragraph read
Leans BUY — composite score +0.39 (BUY). Technicals: RSI 36.07, MACD bearish, price below SMA50. Fundamentals: margin 0.0%. Financial results: last EPS surprise -48.5%, next earnings 2026-11-04. Smart Money Concepts: BOS bullish (trend continuation), price retesting a bullish order block. FinGPT news read: neutral. Internet research: RVMD’s **bull case** centers on Revolution Medicines’ RASONQUE oncology franchise: the company has started a Phase 3 pancreatic-cancer trial, received FDA Breakthrough Therapy Designation for first-line disease, and retains strong analyst support with consensus targets materially above the recent share price. The **bear case** is that RVMD remains unprofitable, reported a larger-than-expected quarterly loss, has no established revenue base, and faces substantial cash burn and clinical-execution risk. A major recent catalyst was the October 5 start of the Phase 3 RASolute 309 trial, alongside a $250 million debt draw that may support commercialization and pipeline development. Shares also rose after RBC lifted its target to $260, though notable insider selling and elevated valuation remain counterpoints. Suggested levels: entry $190.97, target $216.15, stop-loss $173.7, exit by 2026-11-03 (exit before next earnings (2026-11-04) -- this signal doesn't price in that report).
Past ratings for RVMD
| Date | Verdict | Confidence | Price | Move since | |
|---|---|---|---|---|---|
| Oct 15, 2026 | BUY | 39% | $190.97 | — |
"Move since" compares each call's price with the latest analysed price.
Recent news on RVMD
Oct 15, 2026 · Revolution Medicines' RASONQUE (daraxonrasib) Receives Positive CHMP Opinion Recommending Marketing Authorization in European Union for Metastatic Pancreatic Cancer
- Oct 15, 2026: Revolution Medicines' RASONQUE (daraxonrasib) Receives Positive CHMP Opinion Recommending Marketing Authorization in European Union for Metastatic Pancreatic Cancer (GlobeNewswire)
Frequently asked questions
Is RVMD a buy right now?
As of Oct 15, 2026, our automated model rates Revolution Medicines, Inc. (RVMD) BUY with 39% confidence: most of the technical, fundamental, money-flow and news signals point to upside. This is a model output for education, not personal investment advice.
What is the price target for RVMD?
The model's most recent plan targets $216.15 with a stop-loss at $173.70, from an entry near $190.97.
What does a BUY rating mean?
A BUY rating means most of the technical, fundamental, money-flow and news signals point to upside.
For information and education only. Not investment advice. Ratings are produced by an automated model, can be wrong, and may be out of date. Do your own research; you can lose money investing. The site's author may hold positions in stocks discussed here.